Virologic (NASDAQ:VLGC)
Historical Stock Chart
From Jun 2019 to Jun 2024
ViroLogic Added to the NASDAQ Biotechnology Index
SOUTH SAN FRANCISCO, Calif., May 20 /PRNewswire-FirstCall/ -- ViroLogic, Inc.
(NASDAQ:VLGC) announced today that it will be added to the NASDAQ Biotechnology
Index(R) (NASDAQ:NBI) effective with the market open on May 23, 2005.
All securities are classified according to the FTSE Global Classification
System(TM) as biotechnology or pharmaceutical. Index eligibility criteria
include listing on the NASDAQ National Market(R) and meeting minimum
requirements for market value, average daily share volume and seasoning as a
public company.
The Index is ranked on a semi-annual basis in May and November. For more
information about the NASDAQ Biotechnology Index, including eligibility
criteria, visit http://www.nasdaq.com/ .
About ViroLogic
ViroLogic is a biotechnology company advancing individualized medicine by
discovering, developing and marketing innovative products to guide and improve
treatment of serious infectious diseases and cancer. The Company's products are
designed to help doctors optimize treatment regimens for their patients that
lead to better outcomes and reduced costs. The Company's technology is also
being used by numerous biotechnology and pharmaceutical companies to develop
new and improved antiviral therapeutics and vaccines as well as targeted cancer
therapeutics. More information about the Company and its technology can be
found on its web site at http://www.virologic.com/.
FORWARD LOOKING STATEMENTS
Certain statements in this press release are forward-looking, including
statements regarding the addition of ViroLogic to the NASDAQ Biotechnology
Index. These forward-looking statements are subject to risks and uncertainties
and other factors, which may cause actual results to differ materially from the
anticipated results or other expectations expressed in such forward- looking
statements. These risks and uncertainties include, but are not limited to,
risks and uncertainties relating to the development of future products; the
performance of our products; our ability to successfully conduct clinical
studies and the results obtained from those studies; whether larger
confirmatory clinical studies will confirm the results of initial studies;
whether larger studies involving tumor samples will yield favorable results
regarding the predictive capability of eTag assays for responsiveness to cancer
drugs; our ability to establish reliable, high-volume operations at
commercially reasonable costs; our ability to introduce a product commercially
in 2006; our ability to successfully integrate the operations of ACLARA into
our operations; competition from larger more established diagnostic providers;
actual market acceptance of our products and adoption of our technological
approach and products by pharmaceutical and biotechnology companies; our
estimate of the size of our markets; our estimates of the level of demand for
our products; the timing and ultimate size of pharmaceutical company clinical
trials; whether payors will authorize reimbursement for our products; whether
the FDA or any other agency will seek to regulate ViroLogic's in house clinical
laboratory testing; our ability to comply with FDA regulations in order to
establish and maintain diagnostic kit manufacturing operations; whether we will
encounter problems or delays in establishing and validating eTag assays within
our clinical laboratory; whether we will encounter problems or delays in
automating our processes or expanding our capacity; whether the intellectual
property underlying the Company's technology is adequate; whether we may be
deemed to infringe on the intellectual property of others and whether licenses
to third party technology will be available; whether ViroLogic is able to build
brand loyalty and expand revenues; the potential impact of any payments under
the CVRs on our common stock and capital resources; and whether ViroLogic will
be able to raise sufficient capital when required. For a discussion of other
factors that may cause ViroLogic's actual events to differ from those
projected, please refer to the Company's most recent annual report on Form 10-K
and quarterly reports on Form 10-Q, as well as other subsequent filings with
the Securities and Exchange Commission. We do not undertake, and specifically
disclaim any obligation, to revise any forward looking statements to reflect
the occurrence of anticipated or unanticipated events or circumstances after
the date of such statements.
DATASOURCE: ViroLogic, Inc.
CONTACT: Alfred Merriweather, Vice President and CFO of ViroLogic, Inc.,
+1-650-635-1100; or Carolyn Bumgardner Wang of WeissComm Partners,
+1-415-946-1065, or , for ViroLogic, Inc.
Web site: http://www.virologic.com/